Rexahn Pharmaceuticals, Inc. (REXN)

[n3m3sis]

The only possible saving grace..........

Is that they have 3 catalysts scheduled for information release in Q4

RNN
$2.84
-0.22 (-7.19%) Supinoxin
Triple negative breast cancer
Phase 2a 4Q 2017 12/31/2017
Phase 2a initial data due 4Q 2017.
RNN
$2.84
-0.22 (-7.19%) RX-3117
Relapsed and refractory pancreatic cancer
Phase 2 4Q 2017 12/31/2017
Updated Phase 2a data presented at ASCO GI January 20, 2017. Further data due 4Q 2017.
RNN
$2.84
-0.22 (-7.19%) Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a 4Q 2017 12/31/2017
Phase 2a second stage enrollment commenced February 2016. Initial data due 4Q 2017.

Perhaps the funds are needed to push these forward or they expect big things, given that they probably know where the results are going.

I'm going to buy more..... just gotta feeling something big is coming out of those 3 catalysts.